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Abstract Public health vaccination guidelines cannot be
easily transferred to elite athletes. An enhanced benefit from
preventing even mild diseases is obvious but stronger
interference from otherwise minor side effects has to be
considered as well. Thus, special vaccination guidelines for
adult elite athletes are required. In most of them, protection
should be strived for against tetanus, diphtheria, pertussis,
influenza, hepatitis A, hepatitis B, measles, mumps and
varicella. When living or traveling to endemic areas, the
athletes should be immune against tick-borne encephalitis,
yellow fever, Japanese encephalitis, poliomyelitis, typhoid
fever, and meningococcal disease. Vaccination against
pneumococci and Haemophilus influenzae type b is only
relevant in athletes with certain underlying disorders.
Rubella and papillomavirus vaccination might be consid-
ered after an individual risk–benefit analysis. Other vacci-
nations such as cholera, rabies, herpes zoster, and Bacille
Calmette–Gue´rin (BCG) cannot be universally recom-
mended for athletes at present. Only for a very few diseases,
a determination of antibody titers is reasonable to avoid
unnecessary vaccinations or to control efficacy of an indi-
vidual’s vaccination (especially for measles, mumps,
rubella, varicella, hepatitis B and, partly, hepatitis A).
Vaccinations should be scheduled in a way that possible side
effects are least likely to occur in periods of competition.
Typically, vaccinations are well tolerated by elite athletes,
and resulting antibody titers are not different from the gen-
eral population. Side effects might be reduced by an optimal
selection of vaccines and an appropriate technique of
administration. Very few discipline-specific considerations
apply to an athlete’s vaccination schedule mainly from the
competition and training pattern as well as from the typical
geographical distribution of competitive sites.
Key Points
Risk–benefit analysis of vaccination in elite athletes
differs significantly from that of the general
population, providing the rationale for specific
vaccination guidelines
Risk of infection is higher in athletes due to
worldwide traveling and close contact with
teammates or opponents. Moreover, consequences of
infection are more serious, since even mild infections
might be relevant for individual performance
Adverse reactions could be reduced by selecting the
optimal vaccine, the optimal time point for
vaccination and the correct vaccination technique
1 Introduction
Prevention of infection is a key issue in the healthcare of
athletes. Exposure prophylaxis (e.g. avoiding mosquito or
animal bites, avoiding contact with infected individuals,
food, and personal hygiene) and vaccination play major
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roles in these matters. Although this article focuses on
vaccination of adult athletes only, vaccination of the staff
or family members is similarly important to create herd
immunity and to reduce the risk for the athlete to get in
contact with an infectious agent.
Among team doctors and other physicians there exists
some uncertainty about the most appropriate vaccination
regimens in athletes. Some typical circumstances of athletes’
daily life, such as frequent travelling to foreign countries or
close contact with teammates and opponents, might indicate
the need for a modification of recommended vaccination
schedules. In addition, intense physical activity of training
and competition with its possible effects on the immune
function can affect decisions about execution and timing of
vaccination. Such a complex situation warrants a detailed
review of the most current scientific literature with regard to
these issues. It is intended to deduct valid recommendations
for the available vaccines from an international perspective.
An important prerequisite for an immunization campaign in
athletes is probably the acceptance of vaccination require-
ments by opinion formers in the clubs or organizations.
Moreover, all staff members should be vaccinated as role
models and to provide herd immunity.
2 Principles of Vaccination in Elite Athletes
2.1 Existing Vaccination Recommendations
In many countries, considerably different vaccination
guidelines have been established and change over time [1–
5]. These guidelines target mainly on public health issues
and focus on the general population rather than on indi-
viduals with a different benefit–risk profile. Several
potential reasons exist for not recommending an available
vaccine for the general population or for a defined sub-
group. Besides few vaccines with an adverse medical risk–
benefit ratio, the majority of vaccines are not generally
recommended since the medical benefit is not regarded
sufficiently balanced with the costs from the view of the
general population (cost effectiveness), although being
potentially beneficial in a specific individual [6, 7]. Some
guidelines address this problem by an ‘opening clause’
indicating that even vaccinations not recommended by the
guideline may be beneficial on an individual basis. Thus,
they might be offered despite the lacking general recom-
mendation [2].
2.2 Risk–Benefit Balance for Vaccination in Elite
Athletes
In many aspects, the medical risk–benefit balance in elite
athletes differs significantly from that of the general
population [8]. Obviously, this might also affect cost-
effectiveness considerations.
2.2.1 Vaccination is More Beneficial
Infections have a different significance in competitive
sports. For elite athletes, even mild diseases that would
never cause absenteeism in the general population are
relevant for their individual performance. Seemingly trivial
infections might well impair general well-being (or the
athlete’s perception of being perfectly prepared) and rep-
resent an obstacle for the realization of maximal perfor-
mance. Also, with the knowledge of a player’s infection,
team coaches may tend to leave them on the bench. The
same is true for long-lasting infections and post-infectious
periods without full recovery of physical performance.
When white-collar workers have already gone back to
work, elite athletes are still clearly impaired or even unable
to train and compete. Furthermore, some infections which
typically cause only mild diseases in rare cases might result
in severe complications such as myocarditis. This is a well
known fact for at least the influenza virus. Athletes are
potentially more prone to such organ infections than sed-
entary individuals, particularly during strenuous training
and competition. Although evidence is mainly from animal
studies, the severity of the disease renders this assumption
tenable [9–11].
The spectrum of infectious agents potentially affecting
athletes is different from that of the general population.
Elite athletes are often frequent travelers and, thus, prone to
acquire infections not prevalent in their home countries.
Also, they frequently have contact with teammates or
opponents from countries with a different profile of ende-
mic diseases. Thus, a worldwide spectrum of infectious
agents has to be considered.
Close contact with opponents and teammates favors
transmission of many diseases, particularly respiratory-
transmitted diseases [12, 13]. Typically, a contact of less
than 1–2 m distance is necessary to transmit diseases such
as influenza or other respiratory-transmissible infectious
agents such as varicella [14, 15]. For blood-borne dis-
eases, the transmission risk due to sport seems to be less
pronounced, however still slightly higher than in the
general population [16, 17]. Even healthy non-immune
athletes being exposed to an infectious agent (contact with
a diseased individual) might be excluded from training
and competition for medical reasons. Usually such
exclusion has to last for the complete incubation period of
a disease (up to 3 weeks). That does not apply to vacci-
nated and thus immune athletes. Such a kind of prophy-
laxis was performed during the H1N1 influenza pandemic
or recently during a mumps outbreak in the French rugby
league [18].
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Taken together, these facts argue in favor of a more
aggressive vaccination policy since the elite athletes might
benefit from a vaccine far more than the general population.
2.2.2 The Risk from Vaccination is Higher
Similar to the risk due to infection, the risks of vaccination
are aggravated in athletes. At present, no long-term adverse
effects occurring some years after vaccination have been
identified using post-licensure passive surveillance notifi-
cation systems such as the vaccine adverse event reporting
system (VAERS; https://vaers.hhs.gov/index) in the US or
similar notification systems [19]. Thus, only side effects
manifesting shortly after vaccination have to be considered.
These side effects of vaccines include (1) local reactions at
the site of inoculation with the vaccine; (2) generalized
reactions, e.g. allergic reaction or a usually mild disease,
including fever, lymph node swelling, and headache; and
(3) vaccine-specific symptoms that might mimic the dis-
ease aimed to prevent when using live vaccines.
2.2.2.1 Local Reactions Local reactions occur frequently
and early after application (6–72 h) and resolve within not
more than 7 days [20, 21]. These local reactions are of
minor importance in the general population and typically
do not interfere relevantly with business requirements [22–
25]. However, this is not necessarily true in athletes.
Modern vaccines can be administrated by injection (intra-
muscular, subcutaneous, and intradermal), as a nasal spray
or as an oral vaccine (Table 1). Local reactions differ
clearly, dependent on the route of administration. In vac-
cines administered by injection, pain, swellings, or indu-
rations are frequently found. In a few cases (*1 % in
children) itchy subcutaneous nodules (granuloma) appear.
Aluminium-adsorbed vaccines administrated to the subcu-
tis cause this phenomenon, which is suspected to be related
to a contact allergy to aluminium [26].
When using the intradermal route (e.g. for influenza),
local reactions are mainly erythema (7 % of all vaccina-
tions) and swelling (15–30 %) [27, 28]. Vaccines applied
intranasally result in a significantly higher rate of local
symptoms, as shown for the influenza vaccine. A runny
nose was reported in *50 % and a sore throat in *25 %
[29]. Very few vaccines are administrated orally and rep-
licate in the gut. This replication might result in gastroin-
testinal symptoms and vaccinees can excrete the vaccine
virus or bacteria for some weeks or months [30–32].
2.2.2.2 Generalized Reactions Next to syncopes or col-
lapses, which are more related to the injection itself than to
the vaccine (see Sect. 5), generalized reactions may occur,
including fever, headache, fatigue, or lymph node swelling.
Depending on the definition of adverse reactions, the
vaccine and the vaccinated cohort, the frequency of gen-
eralized adverse reactions might differ significantly [33–
35]. These generalized reactions indicate an immunologi-
cal reaction caused by the vaccine [36–38]. These reactions
might be present during the first days after vaccination [35,
39, 40]. Next to these usually mild general reactions,
severe reactions rarely occur, such as anaphylactic or
anaphylactoid reactions, and they probably have the same
relevance for sportsmen and the general population.
Severe acute allergic reactions rarely occur (*1:10 mil-
lion doses for influenza vaccine or measles vaccine) and
manifest immediately after vaccination (seconds to 1 h) [41,
42]. However, anaphylactoid reaction is more common
(*1:100,000) [42]. Subacute allergic reactions appear a
little later (some hours–2 days) and are usually characterized
by urticaria, swellings, and exanthema. Delayed allergic
reactions manifest some days to 1 week after vaccination
(e.g. vasculitis after hepatitis B vaccination [43].
Guillain–Barre´ syndrome (GBS) is a very rare event
after vaccination with modern vaccines and occurs with a
frequency of 1:1 million vaccinations or less [44, 45].
Other hypothetical side effects of vaccination have almost
been ruled out, such as multiple sclerosis, diabetes mellitus
type 1, or autism [46–49].
2.2.2.3 Vaccine-Specific Reaction Live vaccines against
measles, mumps, rubella, varicella, yellow fever, cholera,
poliomyelitis, or typhoid fever might cause a mild vaccine
disease [50, 51]. This is due to the fact that live vaccines
are only attenuated and viruses or bacteria replicate in the
body. Thus, a mild disease might occur, mimicking the
disease the vaccine was designed for. Fever and/or a few
vesicles after varicella vaccination, elevated transaminases
after yellow fever vaccination, meningitis after mumps
vaccination, benign thrombocytopenic purpura after mea-
sles vaccination, or arthritis after rubella vaccination have
been reported [48]. These symptoms normally occur after
10–14 days at the peak of replication. This should be
considered for the timing of a vaccination (see Sect. 4). The
frequency of some of these reactions is related to the
vaccine strain, as shown for aseptic meningitis after mumps
vaccination. Strains used in older vaccines such as Urabe
had a much higher rate of aseptic meningitis compared
with modern strains such as Jeryl Lynn strain [47, 52, 53].
2.3 Rationale for Vaccination Guidelines of Elite
Athletes
As a result of these considerations, elite athletes need
special vaccination guidelines that differ from the ones for
the general population. Taken together, the benefits from
vaccination and the risk from side effects have to be
thoroughly balanced for the situation of an individual
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athlete. Therefore, we discuss the use of vaccines in adult
elite athletes, excluding anthrax and smallpox vaccine,
which are provided for military service only in a few
countries, and excluding rotavirus vaccine since this vac-
cine is only licensed for infants.
3 Indications for Vaccination in Elite Athletes
3.1 Vaccines Recommended for All Athletes
For adult elite athletes, the inactivated vaccines against
tetanus, diphtheria, pertussis, influenza, hepatitis A, hepa-
titis B, and the live vaccines against measles, mumps and
varicella (if immunity is not proven by a natural infection)
are uniformly recommended.
3.1.1 Tetanus and Diphtheria
Tetanus and diphtheria vaccines are implemented in almost
all national guidelines and usually athletes have been
vaccinated during early childhood with basic immunization
(TD). However, in adults, a 10-yearly booster dose with a
reduced diphtheria component (Td) is recommended. It
might be worth mentioning that in many sports, bodily
contact with soil and dust cannot be avoided, as well as the
occurrence of wounds, both of which might favor the
acquisition of Clostridium tetani. Although the risk of
acquiring diphtheria is low, both infections are very severe
and often associated with serious complications, which
further justify their prevention by well-established
vaccinations.
3.1.2 Pertussis
Pertussis vaccination for adults is only recommended by a
few national guidelines in adults such as in Germany, Italy,
France, UK, Austria, and the US, whereas it is not rec-
ommended for all adults in most other EU countries,
Russia, Brazil, or Australia. However, there is growing
evidence that pertussis is affecting adults, resulting in a
variety of severe symptoms of the respiratory system that
Table 1 Administration of vaccines
Vaccine Route of administration











Influenza X X X X
Hepatitis A X Xb
Hepatitis B X Xb
Poliomyelitis X Xb X
Pneumococcal disease Xc Xd
Meningococcal disease Xc
Typhoid fever X X X
Japanese encephalitis X Xb
Rabies X
Papillomavirus X
Bacille Calmette–Gue´rin (BCG) X
a In combination with varicella vaccine, only a subcutaneous injection is possible
b Intramuscular injection preferred; only when an intramuscular injection is not possible, a subcutaneous injection should be considered
c Conjugate vaccines should only be administrated intramuscularly
d Polysaccharide vaccine might be administered intramuscularly or subcutaneously
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might last for many weeks and months. During the last
years, the median age of infected individuals increased in
many countries and thereby adults came into the focus of
vaccination [54]. The risk of a clinically relevant disease is
around 1:500 per year and vaccination reduces this risk by
over 90 % at least for the first 2–3 years after vaccination
[55]. The only licensed vaccine for adults is an acellular
vaccine (with less side effects compared with a whole-cell
vaccine) with a reduced antigen content compared with
childhood vaccines used for basic immunization. At pres-
ent, vaccination against pertussis in adults is only feasible
using a combined vaccine together with tetanus and diph-
theria booster dose [56]. It can well happen that pertussis
vaccine is indicated but tetanus/diphtheria booster doses
were already given within the last years. Earlier, it was
suspected that side effects increase when shortening the
interval between tetanus–diphtheria pre-vaccination and
tetanus–diphtheria–pertussis booster [57]. However, two
recently published reports do not support this hypothesis.
Even within an interval of only 1 month, adverse reactions
did not occur to a higher frequency in individuals recently
pre-vaccinated compared with controls [58, 59]. Thus,
pertussis vaccination is recommended in athletes because
the likelihood of acquiring a severe, long-lasting infection
that interferes with training and competition is relevant,
and the vaccine-associated side effects seem tolerable.
3.1.3 Influenza
Influenza is an important health issue, even in young,
healthy adults. The disease might be severe and the virus is
highly contagious. This alone might constitute sufficient
justification for a recommendation to vaccinate athletes.
Such a consideration is based on the fact that even a
moderate or mild influenza might cause absence from
training and competition for weeks and possibly the loss of
a whole season. Unfortunately, the vaccine efficacy differs
from season to season and is generally less than that of
other vaccines [60, 61]. Influenza vaccination is compli-
cated by the fact that a wide variety of vaccines is avail-
able. Next to a live vaccine that is applied intranasally,
different inactivated vaccines applied via the intradermal or
intramuscular route are available. Moreover, the vaccines
differ in the adjuvants used (with and without MF59),
influencing the antibody production and the likelihood of
adverse reactions. In addition, the antigens in the vaccines
are manufactured differently. At present, sub-unit, split,
and whole-virus vaccines are available. In the majority of
vaccines, the antigens are produced in eggs and less fre-
quently in cell cultures with a slightly different profile in
antibody production and side effects. Finally, for the first
time this season, some vaccines do not only include the two
influenza A (H1N1 and H3N2) and one influenza B
components originating from the Victoria or Yamagata
lineage as an alternative (trivalent vaccine) but also both
influenza B lineages (quadrivalent vaccine). The second
influenza B component was implemented since two influ-
enza B lineages are cocirculating without relevant cross
protection between each other, resulting in an important
lack of protection for the trivalent vaccine. However, the
fourth component is included only in a few vaccines
commercially available [62–65].
Having this high number of different vaccines in mind
when selecting an appropriate vaccine for healthy young
adults that should be accompanied by a minimum of
adverse effects, the use of adjuvanted vaccines is dis-
couraged (more side effects with a benefit that is mainly
detectable in immunosuppressed patients and elderly but
less in healthy young adults) [66, 67]. The use of the
quadrivalent influenza vaccine seems to be beneficial since
quite a high number of influenza virus infections were
caused by an influenza B type not included in the seasonal
vaccine by the World Health Organization (WHO) rec-
ommendation during the last 10 years [68].
Concerning the other vaccine properties, the decision is
less clear. An application by intranasal, intradermal, or
intramuscular route is accompanied by different profiles of
side effects. Efficacy is only slightly different between the
intradermal and the intramuscular route. The intradermal
application differs from the intramuscular application in
the profile of local reactions. Rates of local adverse events
were consistently higher after intradermal application,
particularly erythema, swelling, induration, and pruritus.
However, individuals reported less pain in the muscle after
intradermal application [69]. Taking this into account, the
optimal administration route varies between athletic dis-
ciplines. For a runner, the intradermal route or the deltoid
seems preferable, whereas an archer may benefit from an
intragluteal injection. The intranasally applied live vaccine
(not available with inactivated vaccines) leads to a much
higher protection in young children. With increasing age,
this effect decreases to a level not different or even lower
than for intramuscularly administered vaccines [60, 70].
The live vaccine has some other characteristics that apply
to this kind of vaccine only. While replicating in the upper
respiratory tract, it is possible that the virus might be
transmitted to others within the first 2–3 days (up to
10 days). However, the rate of such transmission seems to
be small (\2 %) [71]. The major benefit of this vaccine is
its favorable profile of side effects without the typical
symptoms of pain, swelling, or induration at the site of
vaccination but with a runny nose or nasal congestion. At
present, for athletes an intramuscular or intradermal
application should be preferred since the live vaccine has
not proven its effectiveness in healthy adults sufficiently
compared with intramuscular vaccines. The live vaccine
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seems to be an option only in a few cases with an ana-
phylactic reaction after intramuscular vaccination or when
local reactions at the injection site must be absolutely
avoided for sport-specific or other reasons.
It should be kept in mind that in the two hemispheres
different vaccines might be recommended and that the
influenza season differs considerably due to the climate.
This means that influenza can be a risk year-round, and
even outside of the typical influenza season when travelling
to countries with differing influenza seasons. Especially
when travelling to the other hemisphere, a twice-yearly
vaccination is essential for optimal protection.
Taken together, vaccination with a quadrivalent intra-
muscular or intradermal administrated influenza vaccine
seems to be the best option for the majority of elite athletes.
3.1.4 Hepatitis A
Hepatitis A is frequently found in many countries around
the world and is mainly a food-borne disease that is
difficult to prevent using simple measures [72, 73]. Its
prevalence is higher in countries with moderate climate
and poor hygiene levels which are frequently chosen for
training camps [74]. Due to the worldwide food market,
even countries with typically low endemicity, such as
Northern Europe, can be affected nowadays [73]. Thus, it
is almost impossible to prevent hepatitis A virus infection
by exposure prophylaxis alone. A vaccination is recom-
mended because this disease typically leads to some
months of reduced physical performance, and hepatitis A
can be easily transferred to teammates and opponents
[75].
3.1.5 Hepatitis B
Hepatitis B is mainly transmitted by blood or genital
secretions. Viral load in infected individuals is rather high,
enabling transmission even when only small amounts of
infected fluids are transmitted. Thus, small injuries with
blood contact to others might be sufficient to transmit the
virus [16, 17]. Consequently, the vaccination is relevant in
all sports with possible contact to blood and body fluids,
such as football, boxing, and hockey, but less so in sports
such as tennis or most winter sports [76]. Moreover, hep-
atitis B is highly prevalent in Africa, parts of Asia, and
Latin America. Contact with the healthcare system in these
countries may harbor an additional risk. Different hepatitis
B vaccines are on the market. Vaccines with various hep-
atitis B surface antigen (HbsAg) concentrations (10, 20,
and 40 lg) are available. Also, the antigens might be dif-
ferent since one vaccine includes not only the small HbsAg
but all three subtypes of HbsAg (small, middle, and large)
with the benefit of a better immune reaction and similar
side effects [77]. In addition, a vaccine with a special
adjuvant (AS04) is available that was mainly designed for
immunosuppressed individuals [78]. For healthy adults, a
20 lg dose without adjuvant AS04 seems to be sufficient.
The other formulations are an option for non-responders
with the need for protection [79]. Hepatitis B vaccination is
strongly recommended in athletes because of the disease
severity (typically several months of no or reduced training
and competition eligibility complicated by irreversible
organ damage) and its contagiosity (likelihood of transfer
to teammates and opponents).
3.1.6 Measles, Mumps, and Varicella
Outbreaks with measles have been reported during sport
events (as reviewed by Pyne and Gleeson [80]). Measles is
an extremely contagious and severe disease with a high rate
of complications (pneumonia, otitis, encephalitis) [81, 82].
There is no doubt that elite athletes should be as immune to
measles as everyone else. In quite a few countries where
big football tournaments took place during the last years, a
measles epidemic occurred at the same time (such as 2006
in Germany, 2010 in South Africa, 2008 in Switzerland/
Austria, 2012 in Poland/Ukraine; Fig. 1). Measles has an
extremely high basic reproduction number R0 of 7–30
(number of cases one case generates on average over the
course of its infectious period, in an otherwise uninfected
population) [83]. This means that even a short-lasting
contact (e.g. with employees in hotels, shops, contact on
streets) might result in an infection.
Mumps infection is a little less severe and contagious
compared with measles with an R0 of 3–10 [84]. However,
it causes a general illness in adults with parotitis and often
(15–20 %) orchitis and meningitis (10 %) as a complica-
tion [85, 86]. Moreover, some sports event had to be can-
celled due to mumps [18, 87, 88]. Immunity after
vaccination is not as high for mumps as it is for measles,
even after two vaccinations. This means that the virus
might circulate, even in countries with a high vaccination
status [89].
Varicella vaccination is important to prevent chicken
pox in all non-immune individuals. The worldwide prev-
alence of antibodies in young adults is relatively high,
mainly due to natural infections. However, up to 10 % of
adults are not immune [90]. Varicella virus is highly con-
tagious (R0 = 7–13) and young adults are often exposed to
(their own) children with chicken pox [91].
All these infections (measles, mumps, and varicella)
have a more severe course in adults compared with chil-
dren. This is particularly true for varicella with pneumonia
and hemorrhagic varicella often with bacterial superinfec-
tion as complications [86, 92, 93]. Thus, there is no doubt
that all elite athletes should be immune against varicella.
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All three live vaccines should be administrated at least
twice in non-immune individuals, with a minimum interval
of 4 weeks [94]. It is recommended to use combined vac-
cines whenever possible [4]. The same applies to rubella
vaccination, which is described later (see Sect. 3.2.3).
3.2 Vaccines Recommended in Special Situations
3.2.1 Vaccines Recommended due to Epidemiological
Reasons Only
3.2.1.1 Tick-Borne Encephalitis, Yellow Fever, Japanese
Encephalitis Since tick-borne encephalitis, yellow fever,
and Japanese encephalitis are solely vector-borne diseases,
they should only be considered when athletes live or travel
to the endemic areas, i.e. Eastern, Central and Northern
Europe, Northern China, Mongolia, and the Russian Fed-
eration for tick-borne encephalitis; Africa and some tropi-
cal parts of South America for yellow fever; and parts of
China, the Russian Federation’s south-east, and South and
South-East Asia (including India and Nepal) for Japanese
encephalitis [95–97]. Consequently, tick-borne encephalitis
was recommended before the 2008 European football
championship in Switzerland and Austria. When athletes
travel to these regions, recommendations do not differ from
the general population due to the severity of these diseases.
3.2.1.2 Poliomyelitis Poliomyelitis is only rarely found
worldwide and at present it occurs only in a few countries
with major social and political problems, such as
Afghanistan, Pakistan, Syria, Somalia, and Nigeria [98].
Without direct contact with these countries (or indirectly
through teammates), the risk of acquiring this infection is
rather low [98]. An oral live vaccine and an inactivated
vaccine for intramuscular injection are available. Again,
both have a different profile of adverse events; the gut is
more often involved when using the oral vaccine [99],
whereas the inactivated vaccine causes side effects at the
injection site [5]. Since the live vaccine harbours the rare
risk to re-mutate to a pathogen, possibly causing outbreaks,
it is discouraged in areas certified by the WHO as polio-
virus-free [40, 98]. The WHO updates the list of countries
with and without poliomyelitis, as well as the poliomyeli-
tis-free region, on their web page [1]. The vaccine to be
chosen for athletes should be the same as recommended by
the national guideline for the general population.
3.2.1.3 Typhoid Fever Typhoid fever is found in some
endemic areas, such as several Asian regions of Russia and
neighboring countries, and in parts of South and South-East
Asia, Africa, and South America [100]. Within the last
10 years, there were large outbreaks in the Democratic
Republic of Congo and Haiti [100]. However, the risk of
transmitting the bacteria is rather small when taking the
travel habits of elite athletes into consideration since these
bacteria are mainly transmitted in the setting of poor
hygiene. At present, three different vaccines are available:
an oral live-attenuated vaccine (Ty21a strain of Salmonella
typhi), a parenteral inactivated vaccine (Vi polysaccharide
vaccine, one dose), and a newly licensed capsular poly-
saccharide vaccine (Vi-rEPA, two doses) for parenteral
use. Efficacy seems to be higher using the new vaccine
(\75 % seroconversion) compared with the two others
(*50 %) [101, 102]. The oral vaccine rarely has side
effects that mainly consist of abdominal discomfort, nausea
and vomiting, whereas with the parenteral vaccines the
local reactions at the site of injection dominate [103].
Theoretically, the live vaccine’s effect can be diminished
by the use of antibiotics. It is thus recommended that this
vaccine should be administered not earlier than 24 h after
an antimicrobial dose [104].
3.2.1.4 Meningococcal Disease Meningococcal vacci-
nation is important at least when travelling to countries
with high endemicity (sub-Saharan Africa from Senegal to
Ethiopia). Moreover, outside of the endemic areas,
meningococcal vaccination is relevant since sporadic
Fig.1 Poster at US airports (this poster was displayed in Boston) after
the 2006 World Cup in Germany, since measles occurred during that
time (photo reproduced with permission from Prof. Dr. Martina
Sester)
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meningococcal meningitis with complication may develop
in healthy individuals, with a high fatality rate of 10–50 %.
The disease peaks in children \6 years of age and in
adolescents and young adults, and thus might play a role
for young athletes [105, 106].
Similar to pneumococcal vaccination (see Sect. 3.2.2), a
conjugate and a polysaccharide vaccine are available. Both
vaccines cover the same subtypes. Immune response to
conjugate vaccines is much better, clearly favoring this
type [107, 108]. The vaccines currently available cover the
serotypes A, C, W135, and Y [109]. In endemic regions,
serotype A is the most prevalent, whereas serotype B
dominates in non-endemic regions [110, 111]. Recently, a
new vaccine was licensed targeting serotype B. Experience
with this vaccine is very limited in healthy adults, thus it
appears too early to recommend vaccination in athletes. If
vaccination with the new serotype B vaccine is considered,
it is strongly recommended to apply it in a resting period
since adverse events with myalgia, arthralgia, headache,
and fever are frequently found [112, 113].
Taken together, vaccination against meningococcal
disease with a conjugate vaccine covering the serotypes A,
C, W135, and Y is recommended when travelling to
endemic areas [109–111]. Vaccination against serotype B
cannot be recommended at present since available data are
too limited.
3.2.2 Vaccines Recommended due to an Underlying
Disorder
3.2.2.1 Pneumococcal Disease Vaccination against
pneumococcal disease is not implemented in national
guidelines for young healthy adults but only for the elderly
and for patients with certain underlying disorders [2, 4,
114]. For athletes, this vaccination should only be con-
sidered in the case of immunocompromizing conditions,
functional or anatomic asplenia, cerebrospinal fluid (CSF)
leaks, or cochlear implants [114]. Moreover, it is recom-
mended for patients with chronic lung diseases such as
asthma [1–5].
Two vaccines are available eliciting a different quality
and quantity of immune response: a conjugated vaccine
including 13 serotypes (PCV-13) at present and a poly-
saccharide vaccine with 23 serotypes (PPSV-23). Vacci-
nation schedules are different for vaccine-naı¨ve individuals
and individuals prevaccinated with the polysaccharide
vaccine. At present, it is considered advantageous for many
underlying diseases that individuals receive one dose of the
conjugate vaccine. A vaccine-naı¨ve individual should
receive the conjugated vaccine first followed by the poly-
saccharide vaccine after 8 weeks, since the opsonophago-
cytic activity seems to be reduced when the two vaccines
are switched [115]. In a few diseases a booster vaccination
is necessary. In these individuals the polysaccharide vac-
cine should be administered 5 years after the last vacci-
nation. In individuals prevaccinated with the
polysaccharide vaccine one dose of the conjugate vaccine
should be used C1 year after the last dose of the polysac-
charide vaccine [114, 116, 117].
3.2.2.2 Haemophilus influenzae Type b (Hib) Similar to
the pneumococcal vaccine, use of the Hib vaccine is only
advised in the rare event of an asplenic athlete. One dose of
Hib vaccine should then be administered [118].
3.2.3 Vaccines with a Critical Medical Benefit–Risk Ratio
in Athletes
3.2.3.1 Rubella Rubella infection causes a much milder
disease compared with measles or mumps and is mainly
asymptomatic, with a rash as the most prominent mani-
festation that is difficult to distinguish from allergic reac-
tion. Fever and other complications are rare [119, 120].
Public health guidelines focus on the prevention of prenatal
rubella infection that may cause embryopathy. Thus, vac-
cination of males targets to break the chain of infections
and to reduce the risk for pregnant women and not to
prevent the disease in non-pregnant women. One important
complication of both the infection and the vaccination is
arthritis for some weeks/months [121–123]. In a random-
ized controlled trial (strain RA27/3 versus saline), women
vaccinated with rubella vaccine reported arthritis in
*30 % (controls *20 %) [124]. Most of the data on
arthritis after vaccination originate from studies of post-
partum vaccination and thus only women were included. It
seems that the risk for arthritis after vaccination in men is
by far lower [122]. Thus, the risks and benefits of a rubella
vaccination have to be considered carefully in an athlete
since arthritis might be considered a more severe problem
than in the general population.
3.2.3.2 Papillomavirus Papillomavirus vaccination
might prevent papillomavirus-associated genitoanal
lesions, cancer, and condyloma accuminata. It is unclear if
athletes are at a higher risk of acquiring sexually trans-
mitted diseases since data on promiscuity in elite athletes
are not available. Vaccination of adults is only recom-
mended in a few countries [125]. Two vaccines are avail-
able: a bivalent vaccine including human papillomavirus
(HPV) 16 and 18, with an adjuvant AS04 and a quadri-
valent vaccine without this adjuvant and, additionally,
HPV 6 and HPV11 (to prevent condyloma accuminata)
[126]. Since the adjuvanted bivalent vaccine has a higher
cross-protection against other high-risk types causing
cancer, this vaccine seems to be of advantage for women
because in women protection against cancer has the highest
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significance [127, 128]. In men, prevention of condyloma
accuminata seems to be of more concern since HPV-
associated cancer in men is found less frequently. Thus, for
men, vaccination with the quadrivalent vaccine including
HPV6 and 11 is probably the best option [125, 129].
3.3 Vaccines not Relevant to Athletes
3.3.1 Cholera
Vaccination against cholera does not seem to be relevant
since cholera is a disease of very poor hygienic level,
classically confined to refugee camps or slums.
3.3.2 Rabies
Rabies vaccination is not recommended since the vaccine
has a high number of considerable side effects and the
disease might be prevented by exposure prophylaxis. It
should be possible to prevent animal bites in athletes by
other measures and, when an incident occurs, post-expo-
sure prophylaxis can be administered even after the bite
[130].
3.3.3 Herpes Zoster
Vaccination against herpes zoster (shingles) does not seem
to be indicated since herpes zoster is only very rarely found
in athletes. There are some anecdotal reports of zoster
occurrence in endurance athletes during highly strenuous
training periods but due to their scarcity no conclusion of
compromised immunity in this particular athlete population
(as a typical precondition for zoster) can be drawn. Also,
vaccination could not be recommended at present since
there are no data on the efficacy in young adults but only in
individuals [50 years of age [51, 131]. The vaccine was
introduced only a short time ago and thus it is too early to
draw any conclusions on a population for which the vac-
cine has not been tested so far.
3.3.4 Bacille Calmette–Gue´rin (BCG)
Bacille Calmette–Gue´rin vaccination is implemented in
many countries for childhood vaccination, whereas vacci-
nation in adulthood is usually not recommended. Although
tuberculosis might be relevant in athletes, especially orig-
inating from countries with high endemicity, the vaccina-
tion of adult teammates does not seem to be beneficial
[132]. This is due to the fact that the vaccination has a
number of severe adverse events since it is a live vaccine
and the bacteria replicate in the body, which might cause
local infection and spread to the regional lymph nodes,
accompanied by lymphadenitis. In rare events, abscesses
can occur. Moreover, since the vaccine does not protect
from primary tuberculosis, the chance of preventing
transmission even within a team is very limited.
4 Timing of Vaccinations
Timing of vaccinations should be chosen with the purpose
of minimizing interference with training and competition
and making sure that the immune reaction is not tempo-
rarily impaired. Relevant side effects after inactivated
vaccines can be expected within the first 2 days after
vaccination, whereas after live attenuated vaccines they are
more likely to occur after 10–14 days when the replication
of the vaccines in the body peaks (see Sect. 2). Under these
constraints, an appropriate time for vaccination which is
not acutely indicated would be at the onset of resting
periods or shortly prior to the winter and summer breaks.
Although indications for increased frequency of upper
respiratory tract infections after strenuous exercise, such as
marathon races, exist [133–135], measurable changes in
immune cell number and function have mainly been docu-
mented within 2 h post-exercise [134, 136, 137] Theoreti-
cally, a compromised immune reaction to vaccinations can
be derived from such observations. However, it has been
shown that influenza vaccination did not lead to decreased
titers when conducted immediately after physical activity
and that acute exercise even increased antibody responses in
pneumococcal vaccination [138–141]. In another study in
elite athletes, titers after hepatitis B vaccination were iden-
tical to the general population [142]. Thus, when a vacci-
nation has to be carried out within a training and/or
competition period (e.g. influenza), there is no major medical
problem with vaccinating shortly after a competition to make
the period of time to the next competition as long as possible.
Acute exercise might even act as a weak adjuvant, increasing
antibody responses slightly in some individuals [138, 139,
141, 143]. In contrast, the pain reaction following the vac-
cination was clearly diminished when vaccinating 6 h after
activity compared with vaccination immediately or 24–48 h
after activity [143]. This indicates that 6-h post-exercise
might represent a preferable point in time.
5 Methods to Reduce Side Effects
Pain, headache, and fever as side effects might be reduced
by co-administering substances such as paracetamol or
ibuprofen, even though antibody titers can be slightly lower
under such circumstances [37]. As already outlined in Sect.
3, another option is to choose a vaccine with a low profile
of adverse events. Side effects of vaccines with more
potent adjuvants, such as MF59, AS03, or AS04, are
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Table 2 Available vaccines: options for antibody titer controls, risk assessment for athletes, and vaccination schedules
Vaccine Titer controla Risk assessment for athletes Vaccination schedule and vaccine
Vaccines recommended for all athletes (see Sect. 3.1)
Tetanus/
diphtheria (Td)
Unnecessary Tetanus: high risk of skin-penetrating injury in
sport. Diphtheria: severe disease
Basic immunization (often in childhood) with at
least three shots. Combination with aP
reasonable; booster after 10 years
Pertussis (aP) Unnecessary Severe disease with relevant impairment of
physical capability; frequently of long duration
Combination with Td. Interval between Td and
TdaP at least 1 month; avoid proximity to
competition (local reactions); combination with
poliomyelitis vaccine; no booster
Influenza Unnecessary High risk due to epidemic spread, highly
contagious
Yearly vaccination. Different seasons and






High risk during training and competition in risk
areas; also possible in first-class hotels
Basic immunization with at least two shots
(months 0, 6–12) as single vaccine or in







High risk in cases of contact (sexually, body
fluids) with athletes from Africa, Asia, South
America, Eastern Europe, or when utilizing the
healthcare system in such countries; small risk
from possible blood contact during training/
competition
Three shots (months 0, 1, 6); shortened schedule
available (days 0, 7, 21, 365). When indicated,
combination with HAV preferred; booster dose
(only HBV) after 10 years. In low-responders
(anti-Hbs 10–100 IU/L) single re-vaccination
without further titer control; in non-responders
(anti-Hbs-titers \10 IU/L) up to three re-
vaccinations, vaccines with high antigen
content preferred
Measles (M) Yes Severe disease with complication in adulthood,
highly contagious, frequent small-area
epidemics
Two shots with a min. interval of 4 weeks;
combined vaccine preferred [MM(R)V]; no
vaccination when immunity is proven by titer




Vaccines recommended due to epidemiological reasons only (see Sect. 3.2.1)
Tick-borne
encephalitis
Unnecessary High infection risk during outdoor activities;
increasing pathogenicity with increasing age.
Eastern, Central and Northern Europe, Northern
China, Mongolia, and the Russian Federation
Basic immunization with at least three shots
(months 0, 1–3, 9–12); shortened schedule
possible (days 0, 7, 21 ? 12–18 months);
booster dose 3–5 years, pay attention to
manufacturer’s advice
Yellow fever NA Severe disease, widely spread in Africa and South
America. International travel regulations




NA Risk only during stays of longer duration (several
months, years) in rural areas of Asia (parts of
China, the Russian Federation’s south-east, and
South and South-East Asia)
Two shots with a min. interval of 4 weeks;
booster after 1 year
Poliomyelitis
(P)
NA Very small risk in only a few areas. Risk with
close contact to population. Currently re-
occurrence in countries where the disease had
been eliminated years ago
Basic immunization (typically in childhood) with
at least two to four shots depending on the
vaccine. In adults without immunity, the
complete schedule should be administered.
When travelling into endemic areas, a single
booster dose is recommended, possibly as
combined vaccine TdaPP
Typhoid fever NA Low transmission risk, typically bound to low
hygiene and contact to local population (Asia,
Africa, South America)
Inactivated vaccines (single shot) or live oral (day
0, 3, 5) preferred, heat-inactivated vaccine in
combination with HAV possible; booster after
3 years with heat-inactivated vaccine or yearly
with live oral vaccine
Meningococcal
disease
NA Low transmission risk but severe disease;
important when travelling to the ‘‘meningitis
belt’’ (Northern Africa, Arabic countries)
Single vaccination with conjugate vaccine against
four types (A, C, W135, Y) preferred; no
booster
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usually more intense although accompanied by higher
antibody titers [66]. Moreover, the profile of local reactions
is mainly based on the route of vaccination. Thus, oral,
intranasal, intradermal, and intramuscular/subcutaneous
routes of administration have a different local reaction
profile.
In vaccines administrated by injection (intramuscularly
or subcutaneously), the local adverse events might be
partly due to the injection techniques. Thus, it is worth
adhering to the correct injection technique (as reviewed by
Petousis-Harris [144]). Dependent on the injection site,
specific impairments may result (e.g. for running, from
buttock pain after a gluteal injection). Obviously, it is
advisable to use the non-dominant side for injections in
unilateral disciplines such as racquet sports. The skin dis-
infectant must be completely dry before injection. Two
separate needles for filling of the syringe and for injection
should be used to avoid granuloma in the subcutis due to
aluminium-containing vaccines [26]. If a vaccine is
allowed to be administrated using the intramuscular or the
subcutaneous route, the intramuscular vaccination seems to
be beneficial (higher titer, lower risk of granuloma).
Injection in the deltoid should be preferred, although other
muscles are possible. It is important that the vaccinee is
sitting or lying and the muscle is completely relaxed.
Longer needles (25 mm) and a fast speed of injection and
withdrawal of the needle (1–2 s) was associated with less
pain [145]. An angle of injection of 90 also reduced pain
in intramuscular injections.
Other adverse reactions often occurring in adolescents and
young adults are syncopes [146, 147]. According to the VA-
ERS, this phenomenon was observed to increase when intro-
ducing papillomavirus vaccine, meningococcal B vaccine,
and pertussis vaccine. Syncopes or collapses may be found at a
frequency of around 1 % [19, 41]. Importantly, not only the
syncope itself but secondary injuries such as skull fracture and
cerebral hemorrhage are of major concern. In the VAERS
reports, around 10 % of all syncopes resulted in hospitaliza-
tion due to secondary injuries. The majority of syncopes
(80 %) occurred within 15 min of vaccine administration,
strongly favoring a 15–30 min observation of a vaccinee
[147]. This observation might be of particular importance in
endurance athletes because there are indications that, in these
athletes, vasovagally-induced syncopes are more frequent
[148]. The consequence would be a prolonged interval of
medical monitoring in vaccinated (endurance) athletes.
Table 2 continued
Vaccine Titer controla Risk assessment for athletes Vaccination schedule and vaccine
Vaccines recommended due to an underlying disorder (see Sect. 3.2.2)
Pneumococcal
disease
NA Low transmission risk but severe disease in
patients with underlying disorders
For optimal protection, start with 13-valent
conjugate vaccine (PCV-13) and, 8 weeks later,
23-valent polysaccharide vaccine (PPSV-23). If
patient already had PPSV-23, the PCV-13
should be added after 1 year. In rare cases,
booster after 5 years
Hib NA Risk only in patients with underlying disorders Single dose, no booster
Vaccines with a critical medical benefit–risk ratio in athletes (see Sect. 3.2.3)





NA Identical risk to general population Three shots (0, 1–2 m, 6 m). Special adjuvanted
vaccine (AS04; HPV 16 and 18) with higher
titers and more local reactions compared with
quadrivalent vaccine (HPV 16, 18, 6, 11)
Vaccines not relevant in athletes (see Sect. 3.3)
Cholera NA Indication only in cases of competition or training
camps in endemic areas (extremely rare)
Oral vaccination; two doses (day 0, 7), booster
after 2 years
Rabies NA Low risk of transmission, high risk of side
effects; exposure prophylaxis possible; post-
exposure vaccination effective
Post-exposure prophylaxis: vaccine (day 0, 3, 7,
14, 28, possibly 90) and hyperimmunoglobulin
(single application)
Herpes zoster NA Very rare in athletes Single vaccination, currently only recommended
for adults [50 years of age
BCG NA Low protection and relevant adverse events Single intradermal application
Hib Haemophilus influenzae B, BCG Bacille Calmette–Gue´rin, Anti-Hbs antibodies against hepatitis B surface antigen, min. minimal, NA
antibody titer controls are not available, or assays are not implemented in routine diagnostics but only in research laboratories
a Titer controls prior to vaccination aimed to avoid vaccination in case of a positive titer; titer control post-vaccination aimed to detect non-
responders qualifying for a re-vaccination
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6 Indications for Titer Control
Since athletes suffer more from side effects of vaccines (as
outlined in Sect. 2), unnecessary vaccinations should be
avoided. This is possible in individuals with pre-existing
immunity due to a natural infection or a previous sufficient
vaccination. Titer controls are generally not supported by
national guidelines since they are often more expensive
than vaccination. Moreover, antibody assays are not stan-
dardized, with the risk of highly different and misleading
results between the assays [149, 150]. However, they might
be well justified in top-level sportsmen to avoid adverse
reactions due to an unnecessary vaccination. This is par-
ticularly true for live attenuated vaccines being more prone
to side effects as well as for athletes from countries where
the likelihood of acquiring natural immunity is high, e.g.
against hepatitis A or B.
Usually, a documented vaccination by a valid vaccina-
tion certificate equals immunity in most cases. In contrast
to this rule, a documented vaccination does not necessarily
mean that vaccination was performed lege artis. This is
why, in certain athletes who have been vaccinated in
countries with doubtful (less immunogene) vaccine quality,
a titer control might be worthwhile, even in cases with
appropriate documentation. Documented examples for less
active vaccines are regions in Eastern Europe or Asia;
however, this might also apply for other regions [151–155].
When in doubt, vaccination documentation from such
countries should not be regarded reliable. After inclusion of
a new team member, the vaccination record should be
carefully checked and, in case of any doubt, a titer control
can be added. This is particularly true for all team members
born and raised in countries with a different vaccination
schedule. In very important vaccination situations, e.g.
with a high risk of infection or in severe diseases, titer
control after vaccination might be justified to be able to
revaccinate quickly in cases of non-response (Table 2).
7 Conclusions
The special situation of elite athletes justifies specified
vaccination guidelines that partly differ from public health
guidelines. The risk of side effects could be reduced by a
correct vaccine and vaccination technique and by the
timing of vaccination. All staff members should also be
vaccinated to increase the acceptance of vaccination by the
athlete.
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